CoChat

The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study

Dini, Saber, Douglas, Nicholas M., Poespoprodjo, Jeanne Rini, Kenangalem, Enny, Sugiarto, Paulus, Plumb, Ian D., Price, Ric N., Simpson, Julie A. · 2020 · BMC Medicine
Cited by 83

The DOI matches its Crossref record.

Abstract

Background: An acute episode of malaria can be followed by multiple recurrent episodes either due to re-infection, recrudescence of a partially treated parasite or, in the case of Plasmodium vivax or P. ovale, relapse from the dormant liver stage of the parasite. The aim of this study was to quantify the impact of recurrent malaria episodes on morbidity and mortality in Papua, Indonesia. Methods: We undertook a retrospective analysis of routinely collected data from malaria patients attending the primary referral hospital in Papua, Indonesia, between April 2004 and December 2013. Multi-state modelling was used to estimate the effect of recurring malaria episodes on re-presentation and admission to hospital and death. The risks of early (≤ 14 days) and late (15 to 365 days) hospital admission and death were estimated separately in our study to distinguish between the direct and indirect effects of malaria recurrence on adverse outcomes. Results: A total of 68,361 patients were included in the analysis, of whom 37,168 (54.4%) presented initially with P. falciparum, 22,209 (32.5%) with P. vivax, and 8984 (13.1%) with other species. During 12 months of follow-up after each of the first four malaria episodes, 10,868 (15.9%) patients were admitted to hospital and 897 (1.3%) died. The risk of re-presenting to the hospital with malaria increased from 34.7% (95% CI 34.4%, 35.1%) at first episode to 58.6% (57.5%, 59.6%) following the third episode of malaria. After adjusting for co-factors, infection with P. vivax was a significant risk factor for re-presentation (hazard ratio (HR) = 1.48 (95% CI 1.44, 1.51)) and late admission to hospital (HR = 1.17 (1.11, 1.22)). Patients infected with P. falciparum had a greater overall rate of mortality within 14 days (HR = 1.54 (1.25, 1.92)), but after multiple episodes of malaria, there was a trend towards a higher rate of early death in patients infected with P. vivax compared to P. falciparum (HR = 1.91 (0.73, 4.97)). Conclusions: Compared to patients initially infected with P. falciparum, those infected with P. vivax had significantly more re-presentations to hospital with malaria, and this contributed to a high risk of inpatient admission and death. These findings highlight the importance of radical cure of P. vivax to eliminate the dormant liver stages that trigger relapses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12916-020-1497-0

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 30

  1. World Health Organization (WHO). World Malaria Report 2018, vol. 2018. Geneva: World Health Organisation; 2016. doi: ISBN 978 92 4 1564403
  2. Douglas NM, Pontororing GJ, Lampah DA, Yeo TW, Kenangalem E, Poespoprodjo JR, et al. Mortality attributable to Plasmodium vivaxmalaria: a clinical audit from Papua, Indonesia. BMC Med. 2014;12:217. https://doi.org/10.1186/s12916-014-0217-z. · DOI
  3. Douglas NM, Poespoprodjo JR, Patriani D, Malloy MJ, Kenangalem E, Sugiarto P, et al. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: a hospital-based cohort study. PLoS Med. 2017;14:e1002379. https://doi.org/10.1371/journal.pmed.1002379. · DOI · Paper page
  4. Devine A, Parmiter M, Chu CS, Bancone G, Nosten F, Price RN, et al. Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: a cost-effectiveness analysis. PLoS Negl Trop Dis. 2017;11:e0005602. https://doi.org/10.1371/journal.pntd.0005602. · DOI
  5. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009;22:430–5. https://doi.org/10.1097/QCO.0b013e32832f14c1. · DOI · Paper page
  6. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 2008;5:e128. https://doi.org/10.1371/journal.pmed.0050128. · DOI · Paper page
  7. Sumawinata IW, Bernadeta, Leksana B, Sutamihardja A, Purnomo, Subianto B, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg. 2003;68:416–20. https://doi.org/10.4269/ajtmh.2003.68.416. · DOI
  8. Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A, Edstein MD, et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine–pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg. 2007;101:351–9. https://doi.org/10.1016/j.trstmh.2006.06.008. · DOI · Paper page
  9. Patriani D, Arguni E, Kenangalem E, Dini S, Sugiarto P, Hasanuddin A, et al. Early and late mortality after malaria in young children in Papua, Indonesia. BMC Infect Dis. 2019;19:922. https://doi.org/10.1186/s12879-019-4497-y. · DOI
  10. Kenangalem E, Poespoprodjo JR, Douglas NM, Burdam FH, Gdeumana K, Chalfein F, et al. Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study. PLoS Med. 2019;16:e1002815. https://doi.org/10.1371/JOURNAL.PMED.1002815. · DOI
  11. Karyana M, Burdarm L, Yeung S, Kenangalem E, Wariker N, Maristela R, et al. Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar J. 2008;7:148. https://doi.org/10.1186/1475-2875-7-148. · DOI
  12. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung R, Laihad F, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet. 2007;369:757–65. https://doi.org/10.1016/S0140-6736(07)60160-3. · DOI · Paper page
  13. Poespoprodjo JR, Fobia W, Kenangalem E, Hasanuddin A, Sugiarto P, Tjitra E, et al. Highly effective therapy for maternal malaria associated with a lower risk of vertical transmission. J Infect Dis. 2011;204:1613–9. https://doi.org/10.1093/infdis/jir558. · DOI
  14. Andersen PK, Keiding N. Multi-state models for event history analysis. Stat Methods Med Res. 2002;11:91–115. https://doi.org/10.1191/0962280202SM276ra. · DOI · Paper page
  15. Putter H, van der Hage J, de Bock GH, Elgalta R, van de Velde CJH. Estimation and prediction in a multi-state model for breast cancer. Biom J. 2006;48:366–80. https://doi.org/10.1002/bimj.200510218. · DOI
  16. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389–430. https://doi.org/10.1002/sim.2712. · DOI · Paper page
  17. de Wreede LC, Fiocco M, Putter H. mstate : An R Package for the Analysis of Competing Risks and Multi-State Models. J Stat Softw. 2011;38:1–30. https://doi.org/10.18637/jss.v038.i07. · DOI · Paper page
  18. Douglas NM, Lampah DA, Kenangalem E, Simpson JA, Poespoprodjo JR, Sugiarto P, et al. Major burden of severe anemia from non-falciparum malaria species in southern Papua: a hospital-based surveillance study. PLoS Med. 2013;10:e1001575. https://doi.org/10.1371/journal.pmed.1001575. · DOI · Paper page
  19. Anstey NM, Douglas NM, Poespoprodjo JR, Price RN. Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol. 2012;80:151–201. https://doi.org/10.1016/B978-0-12-397900-1.00003-7. · DOI · Paper page
  20. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis. 2007;195:927–33. https://doi.org/10.1086/512241. · DOI · Paper page
  21. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis. 2011;52:612–20. https://doi.org/10.1093/cid/ciq249. · DOI · Paper page
  22. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo APP, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis. 2010;10:673–81. https://doi.org/10.1016/S1473-3099(10)70187-0. · DOI · Paper page
  23. Looareesuwan S, White NJ, Chittamas S, Bunnag D, Harinasuta T. High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Lancet (London, England). 1987;2:1052–5. http://www.ncbi.nlm.nih.gov/pubmed/2889965. Accessed 1 Jun 2019 · DOI
  24. Commons RJ, Simpson JA, Thriemer K, Hossain MS, Douglas NM, Humphreys GS, et al. Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19:91–101. https://doi.org/10.1016/S1473-3099(18)30596-6. · DOI
  25. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10:297. https://doi.org/10.1186/1475-2875-10-297. · DOI · Paper page
  26. Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, et al. The anaemia of Plasmodium vivax malaria. Malar J. 2012;11:135. https://doi.org/10.1186/1475-2875-11-135. · DOI · Paper page
  27. Rodríguez-Morales AJ, Sánchez E, Vargas M, Piccolo C, Colina R, Arria M. Anemia and thrombocytopenia in children with Plasmodium vivax malaria. J Trop Pediatr. 2006;52:49–51. https://doi.org/10.1093/tropej/fmi069. · DOI
  28. Menendez C, Fleming AF, Alonso PL. Malaria-related Anaemia. Parasitol Today. 2000;16:469–76. https://doi.org/10.1016/S0169-4758(00)01774-9. · DOI · Paper page
  29. Anstey NM, Russell B, Yeo TW, Price RN. The pathophysiology of vivax malaria. Trends Parasitol. 2009;25:220–7. https://doi.org/10.1016/J.PT.2009.02.003. · DOI · Paper page
  30. Williams TN, Maitland K, Phelps L, Bennett S, Peto TEA, Viji J, et al. Plasmodium vivax: a cause of malnutrition in young children. QJM. 1997;90:751–7. https://doi.org/10.1093/qjmed/90.12.751. · DOI · Paper page

Cited by

See all 83

Metadata

Authors
Dini, S., Douglas, N. M., Poespoprodjo, J. R., Kenangalem, E., Sugiarto, P., Plumb, I. D., Price, R. N., & Simpson, J. A.
Venue
BMC Medicine
Published
2020-02-20
Volume
18
Issue
1
ISSN
1741-7015
Cited by
83
References
0
Language
en
Licence
Funders
  • NHMRC Project Grant (1100394)
  • ARC Discovery Project (DP170103076)
  • Wellcome Trust Senior Fellow in Clinical Science (200909)
  • Australian NHMRC Senior Research Fellowship (1104975)
  • Australian Centre for Research Excellence in Malaria Elimination (1134989)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study. https://app.cochat.ai/papers/10.1186/s12916-020-1497-0
The paper
Dini, S., Douglas, N. M., Poespoprodjo, J. R., Kenangalem, E., Sugiarto, P., Plumb, I. D., Price, R. N., & Simpson, J. A. (2020). The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study. BMC Medicine. https://doi.org/10.1186/s12916-020-1497-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.